Last reviewed · How we verify
UB-312
At a glance
| Generic name | UB-312 |
|---|---|
| Sponsor | United Neuroscience Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- UB-312 in Patients With Synucleinopathies (PHASE1)
- Study of UB-312 in Healthy Participants and Parkinson's Disease Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UB-312 CI brief — competitive landscape report
- UB-312 updates RSS · CI watch RSS
- United Neuroscience Ltd. portfolio CI